NGHIÊN CỨU MỘT SỐ ĐẶC ĐIỂM CẬN LÂM SÀNG VÀ ĐỘT BIẾN EXON 2 GEN KRAS CỦA 35 BỆNH NHÂN UNG THƯ ĐẠI TRỰC TRÀNG TẠI BỆNH VIỆN TRƯỜNG ĐẠI HỌC Y DƯỢC CẦN THƠ NĂM 2021

Abstract

Background: In colorectal cancer, drugs targeting the EGFR molecule only benefit patients (patients) who do not have KRAS gene mutations, in which mutations on exon 2 accounts for 30%-50%. Objectives: To investigate some subclinical characteristics and mutations in exon 2 KRAS genes in 35 colorectal cancer patients at Can Tho University of Medicine and Pharmacy Hospital in 2021. Materials and methods: a cross-sectional descriptive study on 35 patients diagnosed with colorectal cancer at the Hospital of CTUMP in 2021. Result: 21/35 (60%) of the study subjects were male; 88.6% of patients aged 40-69 years; 48.6% of patients had residence in Can Tho; 51.4% of tumors are located in the colon; 60% of patients had elevated CEA; 94.3% of cancers were adenocarcinoma and 91.4% of moderately differentiated tissues. The prevalence of KRAS exon 2 mutation was 48.6% and this rate had a statistically significant relationship with the place of residence (p=0.028) and the CEA index (p=0.009). Conclusion: of 35 patients diagnosed with colorectal cancer, 17/35 (48.6%) had mutations in exon 2 KRAS gene. Place of residence, CEA index has a statistically significant relationship with the mutation prevalence.